Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EXYN vs MDCX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MDCX Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 6–2 Matrix Metrics)

MDCX Overall Winner 6-Pillar Tally: EXYN 0 – 3 MDCX (3 Tie) Matrix Metrics: EXYN 2 – 6 MDCX

As of Nov 20, 2026, Medicus Pharma Ltd. (MDCX) is the stronger overall head-to-head candidate over EXYN (EXYN) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EXYN carries a Unified Composite Score of 50.1/100 (HOLD) at $1.56 (N/M Forward P/E, N/A operating margin), whereas MDCX carries 49.2/100 (HOLD) at $1.14 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While EXYN currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. MDCX 49.2/100 HOLD), MDCX captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: EXYN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.5); meanwhile MDCX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 36.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EXYN vs MDCX
EXYN US Equity
EXYN
Institutional Equity
$1.56
-9.57% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.90β · 85% Vol
Unified Composite Score
50.1 / 100 HOLD
Tech 53.0 Fund 52.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 31
RSI-14: 30.5 · SMA20: $2.19 · SMA50: $2.36
MDCX NASDAQ Head-to-Head Winner
Medicus Pharma Ltd. Common Stock
Pharmaceutical Preparations
$1.14
-2.16% 1D
Market Cap $3.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.28β · 118% Vol
Unified Composite Score
49.2 / 100 HOLD
Tech 40.0 Fund 48.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 36.1 · SMA20: $1.85 · SMA50: $1.40

6-Pillar Scorecard Institutional Category Breakdown (EXYN 0 – 3 MDCX)

Columns: Metric · EXYN · MDCX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale MDCX
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $3.1M
3. Profitability & Quality MDCX
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -7446.1%
4. Balance Sheet & Cash Flow MDCX
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $3.8M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EXYN (2) vs MDCX (6)
Institutional Metric EXYN MDCX Criterion Row Edge
Market Capitalization
Scale
N/A $3.1M Larger Scale MDCX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth MDCX
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin MDCX
Net Profit Margin
Profitability
N/A 0.0% Higher Margin MDCX
Return on Equity (ROE)
Capital Efficiency
N/A -7446.1% Higher ROE MDCX
52-Week Range Position
Momentum
2% ($1–$7) 23% ($0–$5) Stronger Trend MDCX
Beta / 30D Volatility
Risk Regime
1.90β · 85% Vol -0.28β · 118% Vol Lower Realized Risk EXYN
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 49.2 / 100 (HOLD) Higher Composite EXYN
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A ($3.8M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EXYN +10.66 pp
EXYN: -46.02% · MDCX: -56.68%
3M Horizon MDCX +373.13 pp
EXYN: -32.18% · MDCX: +340.95%
6M Horizon MDCX +351.2 pp
EXYN: -72.87% · MDCX: +278.33%
1Y Horizon MDCX +347.08 pp
EXYN: -70.0% · MDCX: +277.08%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EXYN vs MDCX. Trailing 12-month operating profitability (EXYN N/A vs MDCX 0.0%) and valuation multiples (EXYN N/M vs MDCX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EXYN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
MDCX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-7446.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EXYN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EXYN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MDCX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MDCX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EXYN Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MDCX Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $3.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EXYN vs MDCX Key Questions & Quantitative Answers

As of Nov 20, 2026, Medicus Pharma Ltd. (MDCX) is the stronger overall head-to-head candidate over EXYN (EXYN) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EXYN carries a Unified Composite Score of 50.1/100 (HOLD) at $1.56 (N/M Forward P/E, N/A operating margin), whereas MDCX carries 49.2/100 (HOLD) at $1.14 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EXYN currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. MDCX 49.2/100 HOLD), MDCX captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: EXYN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.5); meanwhile MDCX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 36.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MDCX leads the Growth & Scale pillar: EXYN posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with MDCX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EXYN generates N/A in USD-normalized revenue versus N/A for MDCX. In operating R&D and SG&A reinvestment, EXYN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MDCX.

EXYN and MDCX trade at balanced relative valuation multiples. EXYN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MDCX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EXYN (N/A ROE) versus MDCX (-7446.1% ROE) capital efficiency.

In options market volatility and institutional positioning, EXYN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.90β · 85% Vol realized risk). By comparison, MDCX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.28β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.